Each week, countless Americans receive prescriptions for GLP-1 receptor agonists, such as Ozempic and Wegovy. These medications—now available in pill form—are transforming medical perspectives on obesity and diabetes, contributing to a trend of ultra-slim celebrities. Many professionals view GLP-1s as, in medical terms, a sort of miracle drug. But still, I find myself questioning something that doesn’t get enough attention: How does a body, which already produces GLP-1 naturally, react when it’s overwhelmed with pharmaceutical doses of the same substance?
GLP-1 isn’t an unfamiliar entity. It’s a hormone your intestines release after meals, sending a signal to your brain that essentially says, “Hold on, you’ve had enough.” The drugs don’t bring something new into the system—they interact with existing receptors, prompting feelings of fullness sooner than normal by sending the message, “You’re full! Time to stop!” In my line of work, we know that if you continuously overstimulate a signaling pathway crucial for the nervous system’s regular functioning, things can start to go awry. Initially, these issues may whisper, but they can grow into loud problems later on.
Recent findings are starting to align with these concerns. Reports indicate that between 40 and 70 percent of users experience gastrointestinal side effects, like acid reflux and chronic diarrhea or constipation. Moreover, studies reveal that those on GLP-1 agonists face a significantly higher risk of gastroparesis (a chronic delay in stomach emptying) and pancreatitis compared to individuals using other weight-loss options. If these figures hold true in practical settings, then most GLP-1 users may encounter some unwanted gastrointestinal ramifications. Yet, current prescribing guidelines don’t emphasize a key question: Does the patient actually have low endogenous GLP-1 levels? At a time when many healthcare providers are focused on personalized medicine, this gap in inquiry is quite notable and risky.
Let’s consider a fictional woman in her late 40s who just wants to shed a few pounds before summer to finally fit into that bikini she bought years ago. She has no diabetes or gastrointestinal history but feels unhappy with her post-pregnancy body. Her primary care physician prescribes semaglutide for weight loss. However, six months later, she wakes up nauseous, feels bloated after tiny meals, and is losing more weight than she anticipated. Her doctor attributes these symptoms to the drug’s effects. Eventually, a gastroenterologist diagnoses her with gastroparesis. Determining whether the medication caused it, accelerated an underlying issue, or simply revealed something pre-existing is nearly impossible. This lack of clarity is exactly the issue at hand.
GLP-1 receptor agonists intentionally slow down gastric emptying—this effect is essential to their design. However, the gut’s nervous system, which controls motility, isn’t designed to handle that level of continuous, pharmacological intervention. In patients who already have normal or high levels of GLP-1, overwhelming those same receptors with long-acting agonists could push an already delicate system beyond its limit.
Demonstrating this on an individual basis is difficult, but the broader trend cannot be ignored. A significant study has found elevated risk figures for gastroparesis and pancreatitis among those using GLP-1 agonists specifically for weight management, rather than diabetes. Additionally, since obesity itself can lead to gastrointestinal issues, each data point is accompanied by a note of caution: Is it the drug or the underlying condition? The truth is, we don’t completely understand, which should encourage prescribers to be more careful.
From a neuroscience standpoint, this is especially frustrating. The gut-brain connection is one of the most sensitive systems in the body. We have substantial evidence showing that persistent changes in gut signaling—whether from opioids, supplements, or antidepressants—lead to adaptations that last even after the medication is discontinued. GLP-1 receptors are not only found in the pancreas and stomach but are also present all along the vagus nerve, brainstem, and hypothalamus. When we prescribe these drugs to individuals whose GLP-1 systems are functioning normally, we aren’t addressing a shortfall; we might actually be amplifying a pre-existing signal. And we’re doing this widely, affecting millions without assessing what we might be disrupting.
The guidelines are lagging behind. Current recommending protocols focus on body mass index and glycemic targets, which provide insight into a patient’s need for weight loss but do little to inform us about their GLP-1 levels. No key guideline suggests checking endogenous GLP-1 before starting treatment. Even more concerning, patients can obtain these drugs without ever seeing a healthcare provider or needing them from a clinical standpoint.
So, what would a more considerate strategy look like? I propose a straightforward solution: Measure a patient’s endogenous GLP-1 levels before prescribing a GLP-1 receptor agonist. This isn’t a novel concept. Medicine usually demands baseline measurements before adjusting hormone-related treatments; we test thyroid levels before prescribing levothyroxine, assess testosterone and estrogen before hormone replacement therapy, and check insulin secretion before selecting diabetes medications. The principle applies similarly here. If a patient’s system is producing GLP-1 at adequate levels, introducing a long-acting agonist wouldn’t fill a gap—it could be escalating a signal that’s already present. Are the potential repercussions worth the risk for both the prescriber and the patient?
To clarify, the evidence linking GLP-1 agonists to gastroparesis and pancreatitis is suggestive rather than conclusive. I’m not asserting these medications are hazardous and should be banned. Rather, I believe the inquiry into who should receive them hasn’t been thorough enough, and obtaining a baseline GLP-1 measurement should be a clear, low-cost first step. It could be as simple as a blood test, yet we still haven’t managed to make the available tests widely usable for prescribers.
This is a manageable challenge for researchers. We need well-designed studies that look into GLP-1 agonist outcomes based on initial endogenous hormone levels—something no prominent clinical trial has attempted. We also need reliable methods for diagnosing functional gastrointestinal disorders in patients on these medications, to ensure side effects aren’t written off as “normal.” This could involve a clinician assessing GI disorder risks before a prescription or, perhaps, pausing medication for a few months to see if symptoms improve. Moreover, we must take the neuroscience into account: GLP-1 receptors in the vagus nerve and brainstem are integral to the same pathways that my field studies for pain sensitivity and chronic GI discomfort.
For clinicians, the ask is straightforward: Think twice before accepting BMI as a sufficient reason for a prescription. Check whether your patient has any functional GI symptom history. The FDA clearly states semaglutide isn’t recommended for those with severe gastroparesis, indicating awareness of the risk. The real question is whether this cautious stance is being considered early enough, before symptoms appear. I suspect it’s not.
Regarding guiding bodies, precision medicine practices seen in oncology and cardiology have yet to extend into metabolic pharmacology. Testing for endogenous GLP-1 levels isn’t standard currently, but it isn’t out of reach, either. The real matter at hand is whether the field is prepared to pause long enough to uncover what’s missing.
GLP-1 receptor agonists are indeed groundbreaking medications. For patients with Type 2 diabetes, or for those with impaired GLP-1 signaling, they signify significant progress. I’m not against these medications; I just believe doctors should be allowed to gather more information before prescribing them.
